Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA.
Nat Commun. 2020 May 8;11(1):2264. doi: 10.1038/s41467-020-16155-2.
ABCG2 is an ABC transporter that extrudes a variety of compounds from cells, and presents an obstacle in treating chemotherapy-resistant cancers. Despite recent structural insights, no anticancer drug bound to ABCG2 has been resolved, and the mechanisms of multidrug transport remain obscure. Such a gap of knowledge limits the development of novel compounds that block or evade this critical molecular pump. Here we present single-particle cryo-EM studies of ABCG2 in the apo state, and bound to the three structurally distinct chemotherapeutics. Without the binding of conformation-selective antibody fragments or inhibitors, the resting ABCG2 adopts a closed conformation. Our cryo-EM, biochemical, and functional analyses reveal the binding mode of three chemotherapeutic compounds, demonstrate how these molecules open the closed conformation of the transporter, and establish that imatinib is particularly effective in stabilizing the inward facing conformation of ABCG2. Together these studies reveal the previously unrecognized conformational cycle of ABCG2.
ABCG2 是一种 ABC 转运蛋白,能够将多种化合物从细胞内排出,这给治疗化疗耐药性癌症带来了障碍。尽管最近有了结构方面的见解,但仍未发现与 ABCG2 结合的抗癌药物,多药转运的机制仍不清楚。这种知识上的差距限制了新型化合物的开发,这些化合物可以阻断或逃避这种关键的分子泵。在这里,我们展示了 ABCG2 在apo 状态下,以及与三种结构上不同的化疗药物结合的单颗粒 cryo-EM 研究。在没有结合构象选择性抗体片段或抑制剂的情况下,静止的 ABCG2 采用封闭构象。我们的 cryo-EM、生化和功能分析揭示了三种化疗药物结合物的结合模式,证明了这些分子如何打开转运蛋白的封闭构象,并确定伊马替尼特别有效地稳定 ABCG2 的内向构象。这些研究共同揭示了 ABCG2 以前未被认识的构象循环。